View : 97 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author김태헌*
dc.contributor.author김휘영*
dc.contributor.author이민종*
dc.contributor.author전호수*
dc.contributor.author이한아*
dc.date.accessioned2024-05-20T16:31:10Z-
dc.date.available2024-05-20T16:31:10Z-
dc.date.issued2024*
dc.identifier.issn1743-9159*
dc.identifier.otherOAK-34895*
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/268443-
dc.description.abstractBACKGROUNDS: It is unclear which patients benefit from resection in intermediate-stage-hepatocellular carcinoma (HCC). The authors aimed to identify high-risk patients for early recurrence among patients with resectable intermediate-stage HCC. METHODS: This multicenter retrospective study included patients who underwent resection or trans-arterial chemoembolization (TACE) for intermediate-stage HCC (2008-2019). Multivariable Cox proportional analysis was performed to identify high-risk patients when treated with resection. A prediction score for 2-year recurrence-free survival (RFS) was developed using the training cohort and validated. The 2-year RFS in each risk group was compared with that in TACE group, after propensity score matching (PSM). RESULTS: A total of 1686 patients were included (480 and 1206 patients in the resection and TACE groups). During a median follow-up of 31.4 months, the 2-year RFS was significantly higher in the resection (47.7%) than in the TACE group (19.8%) [adjusted hazard ratio (aHR)=1.471, 95% CI: 1.199-1.803, P <0.001). On multivariate analysis, alpha-fetoprotein ≥5.0 ng/ml (aHR=0.202), ALBI grade ≥2 (aHR=0.709), tumor number ≥3 (aHR=0.404), and maximal tumor size ≥5 cm (aHR=0.323) were significantly associated with the lower risk of 2-year RFS in the resection group. The newly developed Surgery Risk score in BCLC-B (SR-B score) with four significant risk factors showed an area under the curve of 0.801 for the 2-year RFS and was validated. Based on the SR-B score, low-risk patients had a significantly higher 2-year RFS (training: aHR=5.834; validation: aHR=5.675) than high-risk patients (all P <0.001) did. In a PSM cohort, a low-risk resection group had a significantly higher (aHR=3.891); a high-risk resection group had a comparable 2-year RFS to those treated with TACE (aHR=0.816). CONCLUSIONS: Resection may be beneficial for resectable intermediate-stage HCC based on the SR-B score. Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.*
dc.languageEnglish*
dc.titleIdentification of patients with favorable prognosis after resection in intermediate-stage-hepatocellular carcinoma*
dc.typeArticle*
dc.relation.issue2*
dc.relation.volume110*
dc.relation.indexSCIE*
dc.relation.indexSCOPUS*
dc.relation.startpage1008*
dc.relation.lastpage1018*
dc.relation.journaltitleInternational journal of surgery (London, England)*
dc.identifier.doi10.1097/JS9.0000000000000941*
dc.identifier.wosidWOS:001164676800031*
dc.identifier.scopusid2-s2.0-85185218546*
dc.author.googleLee*
dc.author.googleHan Ah*
dc.author.googleMinjong*
dc.author.googleYoo*
dc.author.googleJeong-Ju*
dc.author.googleChun*
dc.author.googleHo Soo*
dc.author.googlePark*
dc.author.googleYewan*
dc.author.googleKim*
dc.author.googleHwi Young*
dc.author.googleTae Hun*
dc.author.googleSeo*
dc.author.googleYeon Seok*
dc.author.googleSinn*
dc.author.googleDong Hyun*
dc.contributor.scopusid김태헌(57125156300;57219781484)*
dc.contributor.scopusid김휘영(56493773500)*
dc.contributor.scopusid이민종(55917792000)*
dc.contributor.scopusid전호수(57215293394)*
dc.contributor.scopusid이한아(57190980926;5831162710)*
dc.date.modifydate20240601081000*
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE